We are Sorry, This Page doesn't Exist

Vera's disappointing offering follows several others that have been postponed or also missed their price targets......»»

IGM Biosciences Inc., a pre-revenue biotech company developing antibody therapies for cancer, set price targets on Tuesday for an IPO in which it hopes to raise up to $153 million. The Mountain View company is one of three Bay Area businesses that s.....»»

Pivotal Software Inc., a Bay Area-based business that's majority-owned by Dell Technologies Inc., set a price range Monday for an upcoming IPO in which it plans to raise up to $681 million. The 2,500-person company, headquartered in San Francisco and.....»»

The eight-year-old company has hired nearly 800 people, raised more than $870 million and plans to move into one of the East Bay's most iconic spaces as it rolls out an atypical range of products faster, cheaper and in a more environmentally safe way......»»

Deliveroo sets price range of between £3.90 and £4.60 per share as demand for takeout meals has soared during the COVID-19 pandemic......»»

Nineteen companies from the region have now gone public so far this year, on pace to more than double last-year's post-dotcom era record of 74. Here's more on that and other venture and startup news from the region......»»

Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses......»»

Revolution Medicines Inc. hit the top of the IPO target range it boosted this week, raising $238 million as it gets set to begin trading on Thursday. The Redwood City oncology biotech, led by CEO and President Mark Goldsmith, agreed to sell 14 mil.....»»

Greater Philadelphia's housing market is off to a hot start in 2020. Both the median sales price of homes and number of deals closed last month soared to new highs of the last decade for January, according to data provided by MarketStats by ShowingTim.....»»

Revolution Medicines Inc. appears likely to be the second Bay Area IPO of the year, setting price targets on Monday to raise up to $184 million. The Redwood City oncology biotech's filing comes after the region's first IPO, from One Medical clinic ope.....»»

Revolution Medicines Inc. appears likely to be the second Bay Area IPO of the year, setting price targets on Monday to raise up to $184 million. The Redwood City oncology biotech's filing comes after the region's first IPO, from One Medical clinic ope.....»»

Cabaletta Bio Inc. said Friday it priced its initial public offering at $11 a share, selling 6.8 million shares to raise $74.8 million. The clinical-stage biotech priced the deal well below its price rang.....»»

Buffy Buffy recently released Eucalyptus Sheets ($190 for a queen set), made from an eco-friendly eucalyptus fabric.  Sheet sets range in price from $165 to $215 and come in four neutral, naturally dyed colors. The eucalyptus fabric is billed as bei.....»»

BridgeBio Pharma Inc. priced its initial public offering late Wednesday at $17 a share, above its price range of $14 to $16. The biotech sold 20.5 million shares to .....»»

Volkswagen's truck unit Traton narrowed the price range for its initial public offering (IPO) to between 27 euros ($30.74) and 28 euros a share, the lower end of its earlier 27 euros to 33 euros price range, a bookrunner said on Wednesday......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Two young stocks see opposite reactions to their good performances, while AT&T apparently sets a price range for its streaming service......»»

The Funded: 8 Bay Area funding deals, 4 IPO filings and several M&A deals.....»»

Ideaya Biosciences Inc.'s IPO on Thursday didn't raise as much as it wanted, but its stock has stayed above in the black in its first two days as a public company. Meanwhile, another Bay Area biotech company — Personalis Inc. — filed plans for a.....»»

Hookipa Pharma Inc. shares were barely changed in their trading debut on Thursday, after the biotech priced its initial public offering at the low end of its price range. The stock was up a penny at $14.01. The company, which is using arenavirus-based p.....»»